Literature DB >> 29260607

Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis.

T Komai1, H Shoda1, N Hanata1, K Fujio1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29260607     DOI： 10.1080/03009742.2017.1387673

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  4 in total

Review 1.  Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review.

Authors:  Avgoustina Kyriakou; Konstantinos Parperis; Elena Nikiphorou; Savvas Psarelis
Journal:  Rheumatol Int       Date:  2021-01-12       Impact factor: 2.631

Review 2.  New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.

Authors:  Alain Lescoat; John Varga; Marco Matucci-Cerinic; Dinesh Khanna
Journal:  Expert Opin Investig Drugs       Date:  2021-05-13       Impact factor: 6.498

Review 3.  Esophageal Dysfunction in Systemic Sclerosis: An Update.

Authors:  Bo Li; Junqing Yan; Jincheng Pu; Jianping Tang; Shuchang Xu; Xuan Wang
Journal:  Rheumatol Ther       Date:  2021-10-09

4.  Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis.

Authors:  Ahmet Karatas; Burak Oz; Cigdem Celik; Zeynel Abidin Akar; Ramazan Fazil Akkoc; Ebru Onalan Etem; Adile Ferda Dagli; Suleyman Serdar Koca
Journal:  Sci Rep       Date:  2022-02-15       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.